医学
耐受性
加药
中性粒细胞减少症
细胞因子释放综合征
内科学
地塞米松
临床研究阶段
不利影响
术前用药
发热性中性粒细胞减少症
双特异性抗体
药理学
抗体
免疫学
胃肠病学
临床试验
入射(几何)
药效学
药代动力学
外科
免疫原性
肿瘤科
CD3型
抗原
免疫疗法
最大耐受剂量
作者
Muhamed Baljević,Peter VOORHEES,Cesar Rodriguez,Anita D’Souza,Alfred Chung,Eben Isaac Lichtman,Hana Safah,Katja Christina Weisel,Ravi Vij,Hira Mian,Hila Magen,Emma J Searle,John T. Mckay,Neha Korde,Saurabh Chhabra,Anders Svensson,Rajvineeth Kumar Pothacamury,Chetasi Talati,Carli Allendorf,Claudie Hecquet
出处
期刊:Blood
[Elsevier BV]
日期:2026-11-16
标识
DOI:10.1182/blood.2026034590
摘要
Etentamig is an investigational B-cell maturation antigen (BCMA) x CD3 bispecific T-cell engager, composed of a low-affinity CD3 binding domain, potentially reducing cytokine release syndrome (CRS) and infections, a high-avidity bivalent BCMA-binding domain, and retained FcRn binding supporting monthly (Q4W) dosing after a single step-up dose (SUD). We report long-term efficacy and safety from the ongoing, open-label, phase 1 (dose escalation/expansion; NCT03933735) and Arm A of the phase 1b (NCT05650632) studies of etentamig in adult patients with relapsed/refractory multiple myeloma, triple-class exposure, and ≥3 prior lines of therapy (LoT). In phase 1, patients received etentamig 60 mg Q4W or 40 mg Q3W, and in phase 1b, a SUD on Day 1 and 60 mg Q4W on Day 4. Among 146 patients (median age: 68 years; median [range] prior LoT: 4 [3-23]), median follow-up was 13 months (range: 1-48). Objective responses and ≥ very good partial responses occurred in 66% and 54% of patients. Median duration of response and progression-free survival were not reached. Pooled data suggest etentamig has a manageable safety profile, with Grade 3/4 neutropenia and infection occurring in 38% and 23% of patients. In phase 1b Arm A (n=23), overall CRS incidence was 30% (26% Grade 1; 4% Grade 2) with modified dexamethasone premedication and 1 SUD; median onset was 22.3 hours (range: 5.5-29.6) hours, with resolution in 20.7 hours (range: 1.8-131.7). Etentamig's molecular design may be associated with the observed clinical efficacy and tolerability while also potentially supporting extended dosing intervals.
科研通智能强力驱动
Strongly Powered by AbleSci AI